Japan · Delayed Price · Currency is JPY RaQualia Pharma Statistics
Total Valuation
RaQualia Pharma has a market cap or net worth of JPY 21.57 billion. The enterprise value is 21.22 billion.
| Market Cap | 21.57B |
| Enterprise Value | 21.22B |
Important Dates
The next confirmed earnings date is Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RaQualia Pharma has 26.02 million shares outstanding. The number of shares has increased by 11.14% in one year.
| Current Share Class | 26.02M |
| Shares Outstanding | 26.02M |
| Shares Change (YoY) | +11.14% |
| Shares Change (QoQ) | +5.91% |
| Owned by Insiders (%) | 12.52% |
| Owned by Institutions (%) | -5.20% |
| Float | 17.40M |
Valuation Ratios
The trailing PE ratio is 72.98.
| PE Ratio | 72.98 |
| Forward PE | n/a |
| PS Ratio | 5.42 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 6.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.88, with an EV/FCF ratio of -50.41.
| EV / Earnings | 77.74 |
| EV / Sales | 5.33 |
| EV / EBITDA | 21.88 |
| EV / EBIT | 43.94 |
| EV / FCF | -50.41 |
Financial Position
The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.42.
| Current Ratio | 4.46 |
| Quick Ratio | 4.06 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 2.99 |
| Debt / FCF | -6.89 |
| Interest Coverage | 8.19 |
Financial Efficiency
Return on equity (ROE) is 4.38% and return on invested capital (ROIC) is 4.99%.
| Return on Equity (ROE) | 4.38% |
| Return on Assets (ROA) | 2.99% |
| Return on Invested Capital (ROIC) | 4.99% |
| Return on Capital Employed (ROCE) | 5.23% |
| Weighted Average Cost of Capital (WACC) | 7.90% |
| Revenue Per Employee | 62.17M |
| Profits Per Employee | 4.27M |
| Employee Count | 64 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 4.37 |
Taxes
In the past 12 months, RaQualia Pharma has paid 164.00 million in taxes.
| Income Tax | 164.00M |
| Effective Tax Rate | 37.53% |
Stock Price Statistics
The stock price has increased by +111.48% in the last 52 weeks. The beta is 0.83, so RaQualia Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | +111.48% |
| 50-Day Moving Average | 968.64 |
| 200-Day Moving Average | 747.31 |
| Relative Strength Index (RSI) | 41.87 |
| Average Volume (20 Days) | 362,510 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RaQualia Pharma had revenue of JPY 3.98 billion and earned 273.00 million in profits. Earnings per share was 11.36.
| Revenue | 3.98B |
| Gross Profit | 3.27B |
| Operating Income | 483.00M |
| Pretax Income | 437.00M |
| Net Income | 273.00M |
| EBITDA | 970.00M |
| EBIT | 483.00M |
| Earnings Per Share (EPS) | 11.36 |
Balance Sheet
The company has 3.24 billion in cash and 2.90 billion in debt, with a net cash position of 344.00 million or 13.22 per share.
| Cash & Cash Equivalents | 3.24B |
| Total Debt | 2.90B |
| Net Cash | 344.00M |
| Net Cash Per Share | 13.22 |
| Equity (Book Value) | 6.90B |
| Book Value Per Share | 281.91 |
| Working Capital | 4.41B |
Cash Flow
In the last 12 months, operating cash flow was -354.00 million and capital expenditures -67.00 million, giving a free cash flow of -421.00 million.
| Operating Cash Flow | -354.00M |
| Capital Expenditures | -67.00M |
| Depreciation & Amortization | 488.16M |
| Net Borrowing | -588.82M |
| Free Cash Flow | -421.00M |
| FCF Per Share | -16.18 |
Margins
Gross margin is 82.11%, with operating and profit margins of 12.14% and 6.86%.
| Gross Margin | 82.11% |
| Operating Margin | 12.14% |
| Pretax Margin | 10.98% |
| Profit Margin | 6.86% |
| EBITDA Margin | 24.38% |
| EBIT Margin | 12.14% |
| FCF Margin | n/a |
Dividends & Yields
RaQualia Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.14% |
| Shareholder Yield | -11.14% |
| Earnings Yield | 1.27% |
| FCF Yield | -1.95% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RaQualia Pharma has an Altman Z-Score of 3.29 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.29 |
| Piotroski F-Score | 6 |